Your browser doesn't support javascript.
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.
Emmenegger, Marc; De Cecco, Elena; Lamparter, David; Jacquat, Raphaël P B; Riou, Julien; Menges, Dominik; Ballouz, Tala; Ebner, Daniel; Schneider, Matthias M; Morales, Itzel Condado; Dogançay, Berre; Guo, Jingjing; Wiedmer, Anne; Domange, Julie; Imeri, Marigona; Moos, Rita; Zografou, Chryssa; Batkitar, Leyla; Madrigal, Lidia; Schneider, Dezirae; Trevisan, Chiara; Gonzalez-Guerra, Andres; Carrella, Alessandra; Dubach, Irina L; Xu, Catherine K; Meisl, Georg; Kosmoliaptsis, Vasilis; Malinauskas, Tomas; Burgess-Brown, Nicola; Owens, Ray; Hatch, Stephanie; Mongkolsapaya, Juthathip; Screaton, Gavin R; Schubert, Katharina; Huck, John D; Liu, Feimei; Pojer, Florence; Lau, Kelvin; Hacker, David; Probst-Müller, Elsbeth; Cervia, Carlo; Nilsson, Jakob; Boyman, Onur; Saleh, Lanja; Spanaus, Katharina; von Eckardstein, Arnold; Schaer, Dominik J; Ban, Nenad; Tsai, Ching-Ju; Marino, Jacopo.
  • Emmenegger M; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • De Cecco E; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Lamparter D; Health2030 Genome Center, 9 Chemin des Mines, 1202 Geneva, Switzerland.
  • Jacquat RPB; Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.
  • Riou J; Cavendish Laboratory, Department of Physics, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, UK.
  • Menges D; Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland.
  • Ballouz T; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich, Switzerland.
  • Ebner D; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich, Switzerland.
  • Schneider MM; Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, England.
  • Morales IC; Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.
  • Dogançay B; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Guo J; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Wiedmer A; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Domange J; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Imeri M; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Moos R; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Zografou C; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Batkitar L; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Madrigal L; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Schneider D; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Trevisan C; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Gonzalez-Guerra A; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Carrella A; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Dubach IL; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
  • Xu CK; Division of Internal Medicine, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Meisl G; Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.
  • Kosmoliaptsis V; Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.
  • Malinauskas T; Department of Surgery, Addenbrooke's Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK.
  • Burgess-Brown N; NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK.
  • Owens R; Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford, Headington, Oxford OX3 7BN, UK.
  • Hatch S; Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK.
  • Mongkolsapaya J; Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford, Headington, Oxford OX3 7BN, UK.
  • Screaton GR; The Rosalind Franklin Institute, Harwell Campus, Oxford OX11 0FA, UK.
  • Schubert K; Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, England.
  • Huck JD; Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Liu F; Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Pojer F; Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland.
  • Lau K; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Hacker D; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Probst-Müller E; Protein Production and Structure Core Facility, EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland.
  • Cervia C; Protein Production and Structure Core Facility, EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland.
  • Nilsson J; Protein Production and Structure Core Facility, EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland.
  • Boyman O; Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Saleh L; Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Spanaus K; Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • von Eckardstein A; Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Schaer DJ; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
  • Ban N; Institute of Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Tsai CJ; Institute of Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Marino J; Institute of Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland.
iScience ; 26(2): 105928, 2023 Feb 17.
Article in English | MEDLINE | ID: covidwho-2165434
ABSTRACT
Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72'250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Language: English Journal: IScience Year: 2023 Document Type: Article Affiliation country: J.isci.2023.105928

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Language: English Journal: IScience Year: 2023 Document Type: Article Affiliation country: J.isci.2023.105928